The current status of anti-GPCR drugs against different cancers
- Author:
Usman SANA
1
;
Khawer MARIA
;
Rafique SHAZIA
;
Naz ZARA
;
Saleem KOMAL
Author Information
1. Centre for Applied Molecular Biology,87-West Canal Bank Road Thokar Niaz Baig,University of the Punjab,Lahore,Pakistan
- Keywords:
GPCRs;
Anticancer therapy;
Pancreatic cancer;
Colon cancer;
CLL;
Prostate cancer;
Melanoma
- From:
Journal of Pharmaceutical Analysis
2020;10(6):517-521
- CountryChina
- Language:Chinese
-
Abstract:
G protein coupled receptors (GPCRs) have emerged as the most potential target for a number of drug discovery programs ranging from control of blood pressure, diabetes, cure for genetic diseases to treatment of cancer. A panel of different ligands including hormones, peptides, ions and small molecules is responsible for activation of these receptors. Molecular genetics has identified key GPCRs, whose mutations or altered expressions are linked with tumorgenicity. In this review, we discussed recent advances regarding the involvement of GPCRs in the development of cancers and approaches to manipulating the mechanism behind GPCRs involved tumor growth and metastasis to treat different types of human cancer. This review provides an insight into the current scenario of GPCR-targeted therapy, progress to date and the challenges in the development of anticancer drugs.
